Xencor, Inc. (NASDAQ: XNCR) reported Q3 EPS of ($0.25), $0.07 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $3.57 million.

Cash equivalents and marketable securities totaled $197.6 million as of September 30, 2015, compared to $54.7 million on December 31, 2014. The increase reflects the net proceeds of $115.0 million received from completion of Xencor's follow-on financing in the first quarter and net proceeds from partners and collaborators during the first three quarters of 2015 including an upfront payment of $45.0 million received from Amgen in the third quarter.

For earnings history and earnings-related data on Xencor, Inc. (XNCR) click here.